1. Home
  2. WIW vs PGEN Comparison

WIW vs PGEN Comparison

Compare WIW & PGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Western Asset Inflation-Linked Opportunities & Income Fund

WIW

Western Asset Inflation-Linked Opportunities & Income Fund

HOLD

Current Price

$8.68

Market Cap

540.9M

Sector

Finance

ML Signal

HOLD

Logo Precigen Inc.

PGEN

Precigen Inc.

HOLD

Current Price

$3.67

Market Cap

1.5B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
WIW
PGEN
Founded
2004
1998
Country
United States
United States
Employees
N/A
N/A
Industry
Finance Companies
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
540.9M
1.5B
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
WIW
PGEN
Price
$8.68
$3.67
Analyst Decision
Buy
Analyst Count
0
5
Target Price
N/A
$7.67
AVG Volume (30 Days)
229.9K
4.1M
Earning Date
01-01-0001
11-13-2025
Dividend Yield
11.14%
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
$6,309,000.00
Revenue This Year
N/A
$342.78
Revenue Next Year
N/A
$478.46
P/E Ratio
N/A
N/A
Revenue Growth
N/A
59.20
52 Week Low
$8.01
$0.65
52 Week High
$9.37
$5.23

Technical Indicators

Market Signals
Indicator
WIW
PGEN
Relative Strength Index (RSI) 39.10 48.12
Support Level $8.67 $3.42
Resistance Level $8.73 $3.75
Average True Range (ATR) 0.07 0.23
MACD -0.00 -0.02
Stochastic Oscillator 0.00 50.00

Price Performance

Historical Comparison
WIW
PGEN

About WIW Western Asset Inflation-Linked Opportunities & Income Fund

Western Asset Inflation-Linked Opportunities and Income Fund is a diversified, closed-end management investment company. Its primary investment objective of the group is to provide current income for its shareholders. The secondary investment objective is capital appreciation with current income.

About PGEN Precigen Inc.

Precigen Inc is a biotechnology company that develops synthetic biology solutions. The company designs build and regulate gene programs. Its technologies are broadly applicable across a wide range of diverse end markets. Intrexon's business model is to commercialize its technologies through exclusive channel collaborations with collaborators that have specific industry expertise, development resources, and sales and marketing capabilities, in order to bring new and improved products and processes to market. Its reportable segments are Biopharmaceuticals and Exemplar. The company's collaborators provide compensation through technology access fees, royalties, milestones, and reimbursement of certain costs.

Share on Social Networks: